Repligen Corporation $RGEN Shares Acquired by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP increased its Repligen stake by 420.9% in the second quarter, purchasing 9,146 additional shares for a total holding of 11,319 shares valued at approximately $1.54 million. Institutional investors and hedge funds own 97.64% of the company.
• Repligen reported quarterly EPS of $0.54, exceeding estimates of $0.45, while revenue rose 11.9% year over year to $204.13 million. The company issued fiscal 2026 EPS guidance of $2.03–$2.09.
• Shares traded up 3.3% to $190.65, near the 52-week high of $192.49. Analysts maintain an overall “Buy” rating, with an average price target of $168.57, below the current share price.

Corient Private Wealth LP boosted its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 420.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 11,319 shares of the biotechnology company's stock after purchasing an additional 9,146 shares during the period. Corient Private Wealth LP's holdings in Repligen were worth $1,544,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Repligen in the 2nd quarter worth approximately $1,173,000. Angeles Wealth Management LLC raised its position in Repligen by 6.6% in the 2nd quarter. Angeles Wealth Management LLC now owns 2,757 shares of the biotechnology company's stock valued at $376,000 after purchasing an additional 170 shares during the last quarter. Nykredit A S bought a new position in Repligen in the 2nd quarter valued at $269,000. B. Metzler seel. Sohn & Co. AG boosted its stake in Repligen by 52.8% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 26,361 shares of the biotechnology company's stock worth $3,597,000 after purchasing an additional 9,108 shares in the last quarter. Finally, Moore Capital Management LP acquired a new position in Repligen in the second quarter worth $5,123,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Up 3.3%

RGEN opened at $190.65 on Friday. The firm has a 50 day simple moving average of $164.58 and a 200 day simple moving average of $138.56. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $192.49. The company has a market cap of $10.76 billion, a price-to-earnings ratio of 261.16, a price-to-earnings-growth ratio of 3.41 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analysts' expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, sell-side analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current year.

Analyst Ratings Changes

RGEN has been the topic of several research reports. Wolfe Research assumed coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $145.00 price target on the stock. UBS Group boosted their target price on shares of Repligen from $195.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, September 9th. Weiss Ratings raised shares of Repligen from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. raised their price target on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Finally, Wells Fargo & Company boosted their price objective on shares of Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research report on Thursday, July 30th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Repligen presently has an average rating of "Buy" and an average target price of $168.57.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company's portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.